You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.
The company also announced that it has received New York State Department of Health conditional approval for three women's health molecular diagnostic tests.
The GW Index outperformed the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
Revenues from the company's clinical labs segment grew 8 percent this quarter, and revenues from the life sciences business grew 6 percent.
The GenomeWeb Index rose nearly 5 percent in February, on par with the Dow and slightly outperforming the Nasdaq.
The company said revenues from its clinical lab services rose 9 percent because of high demand for certain molecular diagnostic services.
The company also reported FY2016 revenues rose 5 percent year over year, despite a dip in product revenues for the year.
Illumina follows Agilent, Life Technologies, Affymetrix, Siemens, and Luminex in settling lawsuits alleging infringement of US Patent No 7,064,197.
Contributing to the growth was a 16 percent increase in revenues from Enzo's clinical lab services division, which includes its molecular diagnostics offerings.
The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.
Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.
The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.
In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.